Collectively, our results establish that targeted DPP4 inhibition not only mitigates ferroptosis but also ameliorates PCOS-associated endometrial dysfunction, ultimately normalizing receptivity parameters. The gene discussed is DPP4; the disease is polycystic ovary syndrome.